Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.11 (
CD10
)
9,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The main high molecular weight (650K) multicatalytic
endopeptidase
has been purified from postmortem human cerebral cortex. As in other tissues and species, this enzyme is composed of several subunits of 24-31K and has three distinct catalytic activities, as shown by the hydrolysis of the fluorogenic tripeptide substrates glutaryl-Gly-Gly-Phe-7-amido-4-methylcoumarin, benzyloxycarboxyl-Gly-Gly-Arg-7-amido-4-methylcoumarin, and benzyloxycarboxyl-Leu-Leu-Glu-2-naphthylamide with hydrophobic (Phe), basic (Arg), and acidic (Glu) residues in the P1 position, respectively. These activities are distinguishable by their differential sensitivity to peptidase inhibitors. The enzyme hydrolysed neuropeptides at pH 7.4 at multiple sites with widely differing rates, ranging from 113 nmol/min/mg for substance-P, down to 2 nmol/min/mg for bradykinin. The enzyme also had proteinase activity as shown by the hydrolysis of casein. For the hydrolysis of the Tyr5-Gly6 bond in luteinizing hormone-releasing hormone, the Km was 0.95 mM and the specificity constant (kcat/Km) was 4.7 X 10(3) M-1 s-1. The bond specificity of the enzyme at neutral pH was determined by identifying the degradation products of 15 naturally occurring peptide sequences. The bonds most susceptible to hydrolysis had a hydrophobic residue at P1 and either a small (e.g., -Gly or -
NH2
) or hydrophobic residue at P'1. Hydrolysis of -Glu-X bonds (most notably in neuropeptide Y) and the Arg6-Arg7 bond in dynorphin peptides was also seen. Thus the three activities identified with fluorogenic substrates appear to be expressed against oligopeptides.
...
PMID:Multicatalytic, high-Mr endopeptidase from postmortem human brain. 201 52
The specificity of action of a serine proteinase from the microsomal membranes of rat liver was investigated at pH 7.5 and 37 degrees C using various peptides as substrates. HPLC analyses of the peptides produced followed by their amino acid analyses have revealed that the enzyme is a unique
endopeptidase
specifically cleaving arginyl peptide bonds at paired basic amino acid residues. Thus, the enzyme is suggested to be a kind of processing proteinase involved in the conversion of proproteins to their mature forms. Indeed, the enzyme cleaved specifically the
NH2
-terminal 20-residue peptide of proalbumin at the Arg-Arg sequence.
...
PMID:Specific cleavages of arginyl peptide bonds at basic amino acid pairs by a serine proteinase from the microsomal membranes of rat liver. 202 47
Inhibitors of
endopeptidase
(EP) 24.15, an enzyme cleaving the Tyr5-Gly6 bond of LHRH, greatly increase the half-life of i.v. or i.c.v. administered luteinizing hormone-releasing hormone (LHRH) (Lasdun et al., J. Pharmacol. Exp. Ther. 251: 439-447, 1989). Concentrations of plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) were measured in rats after i.c.v. and i.v. administration of LHRH alone or in conjunction with inhibitors of EP 24.15. In animals treated with two potent EP 24.15 inhibitors, i.v. and i.c.v. LHRH injections induced a much greater and longer-lasting increase of plasma LH and FSH concentrations than in controls Two and 4 hr after administration of the inhibitors and LHRH, hormone concentrations were one order of magnitude greater than in controls. The magnitudes and durations of the increases were similar to those after administration of [D-Trp6]-LHRH or [D-Leu6, Des-Gly-
NH2
(10)]-LHRH ethylamide, two "superactive" analogs of LHRH, which are resistant to degradation by EP 24.15, due to the presence of a D-amino acid in position 6. It is concluded that LHRH degradation by EP 24.15 limits the magnitude and duration of the response of the pituitary to LHRH, and that increases in plasma LH and FSH similar to those obtained after administration of superactive analogs can be also obtained with the natural hormone, provided that its degradation is prevented by EP 24.15 inhibitors. Accordingly, the increased in vivo activity of the superactive LHRH analogs can be largely attributed to their resistance to degradation by EP 24.15.
...
PMID:Inhibition of endopeptidase 24.15 greatly increases the release of luteinizing hormone and follicle stimulating hormone in response to luteinizing hormone/releasing hormone. 211 81
The receptor for mouse interferon gamma (IFN-gamma) was purified from detergent-solubilized plasma membranes of EL-4, a thymoma cell line which expresses a high number of receptors on its cell surface. The purification was carried out by immunoaffinity chromatography using an anti-receptor monoclonal antibody. The purified receptor was subjected to
NH2
-terminal sequence analysis as well as sequencing of
endopeptidase
-generated peptides. One of the peptides was found to be identical to a portion of the published amino acid sequence of the human IFN-gamma receptor deduced from cDNA. This information was utilized to construct a mixed-sequence oligodeoxynucleotide probe which permitted the isolation of a full-length cDNA clone coding for the mouse IFN-gamma receptor. The mouse IFN-gamma receptor cDNA is comprised of 105 base pairs of the 5'-untranslated region, an open reading frame coding for a 477-amino acid serine-rich protein having calculated Mr 52,276, and a 3'-untranslated region of 539 base pairs. The receptor is first synthesized as a pre-protein from which a 25-amino acid signal peptide is cleaved. The receptor contains a hydrophobic transmembrane portion near the center of the molecule. Northern blot analysis of various cell lines showed that each contained a single 2.0-kilobase mRNA. A direct correlation between the amount of IFN-gamma receptor mRNA and the level of receptor expressed on the cell surface was observed. The mouse and human IFN-gamma receptors are structurally similar, showing 51% over-all homology in amino acid sequence. Mouse IFN-gamma receptor cDNA when inserted in a mammalian shuttle vector and transfected into COS-7 monkey cells was able to direct the expression of specific binding activity for mouse IFN-gamma.
...
PMID:Affinity purification, peptide analysis, and cDNA sequence of the mouse interferon gamma receptor. 213 61
The central enzymatic stability of des-enkephalin-gamma-endorphin and its synthetic analogs [cycloN alpha 6, C delta 11]beta-endorphin-[6-17] and [Pro7, Lys(Ac)9]-beta-endorphin[6-17] was studied in vitro using a newly developed, regionally dissected rat brain slice, time course incubation procedure. Tissue slice viability was estimated as the ability of the brain slice to take up or release gamma-[3H]aminobutyric acid after high K+ stimulation. Results demonstrated stability of uptake/release up to 5 hr of incubation, suggesting tissue viability over this period. The estimated half-life of peptides based on the results obtained in our incubation protocol suggest that the peptides studied are metabolized at different rates in the individual brain regions tested. A good correlation exists between the high enzyme activity of
neutral endopeptidase
(
EC 3.4.24.11
) and the rapid degradation of des-enkephalin-gamma-endorphin and [cycloN alpha 6, C delata 11]beta-endorphin-[6-17] in caudate putamen. Proline substitution combined with lysine acetylation appears to improve resistance to enzymatic metabolism in caudate putamen and hypothalamus. However, cyclization of des-enkephalin-gamma-endorphin forming an amide bond between the alpha-
NH2
of the N-terminal threonine and the gamma-COOH of glutamic acid did not improve peptide stability in any brain region tested. The present study has shown that the brain slice technique is a valid and unique approach to study neuropeptide metabolism in small, discrete regions of rat brain where peptides, peptidases and receptors are colocalized and that specific structural modifications can improve peptide stability.
...
PMID:Neuropeptide processing in regional brain slices: effect of conformation and sequence. 214 Jan 32
The influence of adrenalectomy and corticosterone substitution was investigated on Leu-Phe cleaving
endopeptidase
activity and on the levels of gamma-endorphin and beta-endorphin in the pituitary gland and the brain. The enzyme activity was quantitated by a specific radiometric assay based on the cleavage of the Leu17-Phe18 bond in a
NH2
- and COOH-terminally protected synthetic substrate which was analogous to beta-endorphin-(15-19). This activity may mimick the formation of gamma-endorphin. beta-Endorphin and gamma-endorphin were measured by specific radioimmunoassays. After 14 days of adrenalectomy enzyme activity had increased in anterior (15%) and neurointermediate lobes of the pituitary gland (30%), hypothalamus (25%), and liver (15%). This increase was prevented when the adrenalectomized animals were subjected to chronic corticosterone substitution by subcutaneous implantation of a pellet of 100 mg. Extirpation of only the adrenal medulla did not affect the Leu-Phe cleaving activity. Enzyme activity in the septum, hippocampus, and cerebellum had not changed after adrenalectomy. Determination of immunoreactive levels of gamma- and beta-endorphins showed that in the anterior pituitary gland gamma- and beta-endorphins had increased by 275 and 300%, respectively, 14 days after adrenalectomy. No significant changes were observed in endorphin levels of the intermediate lobe of the pituitary gland, hypothalamus, hippocampus, and septum. The results indicate that Leu-Phe cleaving
endopeptidase
activity in sensitive to glucocorticoids in tissues containing proopiomelanocortin-producing cells, i.e., anterior and neurointermediate pituitary gland and the hypothalamus. In the anterior pituitary gland it is correlated with the levels of gamma- and beta-endorphins.
...
PMID:Leu-Phe cleaving endopeptidase activity, gamma-endorphin, and beta-endorphin in the rat pituitary gland and brain. Effect of adrenalectomy and corticosterone substitution. 244 2
This report summarizes the recent rapid development of research on
neutral endopeptidase 24.11
(enkephalinase;
NEP
) and on two other metalloenzymes, meprin and endopeptidase 24.15.
NEP
cleaves a variety of active peptides, including enkephalins, at the amino side of hydrophobic amino acids. The cDNA for human, rat, and rabbit
NEP
has been cloned and the deduced protein sequences revealed a high degree of homology (93-94%). Site-directed mutagenesis proved that an active site glutamic acid is involved in catalysis and two active site histidines are responsible for binding the zinc cofactor. Although
NEP
was originally discovered in the kidney, it is widely distributed in the body including specific structures in the central nervous system, lung, male genital tract, and intestine and in neutrophils, fibroblasts, and epithelial cells. In tissues and cells
NEP
is bound to plasma membrane through a hydrophobic membrane-spanning domain near the
NH2
terminus, but it is present in soluble form in urine and blood. In addition to enkephalins,
NEP
cleaves kinins, chemotactic peptide, atrial natriuretic factor (ANF), and substance P in vivo.
NEP
in the lung is a major inactivator of substance P, which constricts the airway smooth muscles. Because of the possible involvement of
NEP
in the metabolism of opioid peptides and the cardiac hormone ANF, orally active inhibitors have been synthesized. Compounds that inhibit both aminopeptidase and
NEP
were reported to prolong the analgesic effects of enkephalins. Other inhibitors given per os prolonged the renal effects of exogenous ANF. A newly synthesized specific inhibitor of
NEP
was also active in animal experiments as an analgesic. Studies on the structure and function of
NEP
should lead to further development of therapeutically applicable inhibitors.
...
PMID:Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. 252 10
The use of high-performance liquid chromatography and fast atom bombardment mass spectrometry are shown to be an efficient combination for investigating protease-mediated digestion of synthetic analogs of the peptide hormone ANF (atrial natriuretic factor). As examples of the reported methodology, rANF5-23-
NH2
and rANF7-23-
NH2
were digested with the
endopeptidase
thermolysin. These truncated analogs were selected to investigate metabolism within the disulfide-linked core of ANF, particularly at the Cys7-Phe8 bond. While this position was the site of initial hydrolysis for rANF5-23-
NH2
(t1/2 = 0.5 min), the Cys7-Phe8 bond remained intact for all observed degradation products of rANF7-23-
NH2
(t1/2 = 16 min). These findings suggest that improved stability towards
endopeptidase
-mediated core hydrolysis may be conferred to analogs of ANF by removal of the first six residues from the N-terminus.
...
PMID:Fast atom bombardment mass spectrometric investigation of in vitro degradation within the disulfide-linked core of atrial natriuretic factor. 252 32
The peptides H-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-
NH2
(rANF8-15-
NH2
), Ac-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-
NH2
(Ac-rANF8-15-
NH2
), and their corresponding retro-inverso-isomeric peptides H-D-Ile-D-Arg-D-Asp-D-Ile-D-Arg-Gly-Gly-D-Phe-
NH2
(D-rANF15-8-
NH2
), Ac-D-Ile-D-Arg-D-Asp-D-Ile-D-Arg-Gly-Gly-D-Phe-
NH2
(Ac-D-rANF15-8-
NH2
), were evaluated for their ability to compete for the binding of 125I-rANF5-28 to cultured spontaneously hypertensive rat (SHR) aortic smooth muscle cell membranes. Their stability toward hydrolysis by the
neutral endopeptidase
thermolysin was also studied. The octapeptides rANF8-15-
NH2
and Ac-rANF8-15-
NH2
bound with IC50's of 367 pM and 1900 pM, respectively, but were rapidly hydrolyzed by thermolysin. Retro-inverso-isomers were prepared to provide molecules with an improved enzymatic stability. The retro-inverso-isomers were completely stable to thermolysin but were virtually inactive in the binding assay (IC50 greater than 1 microM).
...
PMID:Receptor binding affinity and thermolysin degradation of truncated and retro-inverso-isomeric ANF analogs. 254 Dec 91
To determine the role of endogenous
neutral endopeptidase
(
NEP
) (also called enkephalinase,
EC 3.4.24.11
) in regulating neurotensin-induced airway contraction, we used phosphoramidon, a specific
NEP
inhibitor, in the guinea pig. In studies in vitro, neurotensin and the COOH-terminal fragment neurotensin-(8-13) contracted strips of bronchial smooth muscle in a concentration-dependent fashion (P less than 0.001). In contrast, the
NH2
-terminal fragment neurotensin-(1-11) and the COOH-terminal fragment neurotensin-(12-13), the main fragments of neurotensin hydrolysis by
NEP
, had no effect. Phosphoramidon (10(-5) M) did not change resting tension but shifted the concentration-response curves to neurotensin to lower concentrations (P less than 0.001), whereas inhibitors of kininase II, aminopeptidases, serine proteases, and carboxypeptidase N were without effect. Removing the epithelium increased the contractile response to neurotensin (P less than 0.001), and phosphoramidon further increased the response to neurotensin in these tissues (P less than 0.001). Similar results were obtained in studies in vivo using aerosolized neurotensin and phosphoramidon. These results suggest that endogenous
NEP
in the airways modulates the effects of neurotensin on airway smooth muscle contraction by inactivating the peptide.
...
PMID:Neutral endopeptidase modulates neurotensin-induced airway contraction. 274 98
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>